Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.

• Үндсэн зохиолчид: Livingstone Tavul (Зохиогч), Moses Laman (Зохиогч), Cade Howard (Зохиогч), Bethuel Kotty (Зохиогч), Anna Samuel (Зохиогч), Catherine Bjerum (Зохиогч), Kobie O'Brian (Зохиогч), Steven Kumai (Зохиогч), Matthew Amuga (Зохиогч), Lina Lorry (Зохиогч), Zebedee Kerry (Зохиогч), Melvin Kualawi (Зохиогч), Stephan Karl (Зохиогч), Leo Makita (Зохиогч), Lucy N John (Зохиогч), Sibauk Bieb (Зохиогч), James Wangi (Зохиогч), Gary J Weil (Зохиогч), Charles W Goss (Зохиогч), Daniel J Tisch (Зохиогч), William Pomat (Зохиогч), Christopher L King (Зохиогч), Leanne J Robinson (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Public Library of Science (PLoS), 2022-02-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

<h4>Background</h4>Papua New Guinea (PNG) has a high burden of lymphatic filariasis (LF) caused by Wuchereria bancrofti, with an estimated 4.2 million people at risk of infection. A single co-administered dose of ivermectin, diethylcarbamazine and albendazole (IDA) has been shown to have...